StoryFunding
BioAge Labs prices Nasdaq IPO
BioAge priced its initial public offering of 11 million shares at $18 each, raising approximately $198M gross proceeds, and listed on the Nasdaq Global Select Market under the ticker BIOA. The IPO valued the longevity biotech company at the IPO price.
- 11 million shares priced at $18 per share for ~$198M gross proceeds.
- Underwriters received option to purchase up to 1.65 million additional shares at $18 within 30 days.
- Nasdaq listing under ticker BIOA marks public entry for the APJ agonist developer focused on cardiometabolic aging.